GHRP-2: Research Overview and Mechanism

GHRP-2, also known as pralmorelin, is a synthetic six-residue peptide (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) that acts as an agonist of the growth hormone secretagogue receptor, GHS-R1a. Its molecular weight is near 818 g/mol.

It is a later-generation growth hormone-releasing peptide often referenced in research literature within secretagogue-potency comparisons, which is why it appears frequently as a tool compound in somatotroph-pharmacology research.

In laboratory and preclinical research, GHRP-2 is studied for GHS-R (ghrelin) receptor agonism, ghrelin signaling, growth hormone-secretion dynamics, and secretagogue pharmacology. It activates the Gq-coupled GHS-R1a receptor in pituitary somatotrophs and is frequently chosen for its potency in evoking a measurable growth-hormone-secretion response in research models, which makes it a convenient reference agonist within the growth hormone-releasing peptide series alongside GHRP-6 and Hexarelin.

As a molecule, GHRP-2 (pralmorelin) also has a documented clinical footprint: it has been approved in Japan as a diagnostic agent, marketed by Kaken Pharmaceutical under the name GHRP Kaken, used to assess growth-hormone secretion capacity, and has been examined in published human growth-hormone-stimulation research. That regulatory and clinical context is reported here in the third person as public fact about the compound and does not describe this product, which is for research use only and is not approved for human use.

Pinnacle GHRP-2 is a lyophilized hexapeptide (molecular weight near 818 g/mol) stored at -20C and protected from light; once reconstituted with bacteriostatic water it is aliquoted where possible so that repeated freeze-thaw cycling, which can degrade a reconstituted peptide, is kept to a minimum. Each batch is doctoral chemist tested by HPLC and mass spectrometry and ships with a lot-matched Certificate of Analysis confirming identity and purity.